Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | BRD1 | O95696 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007929 | 0.95 | MAP2K4 (0.54) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL27676127 | 0.89 | JAK2 (0.54) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL4015269 | 0.88 | MAP2K4 (0.50) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL4011041 | 0.88 | MAP2K4 (0.53) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL1460607 | 0.88 | KIT (0.52) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL1461652 | 0.84 | MAP2K4 (0.60) | MAP2K4LNPEPKITPGRPTPN2 | |
| SCHEMBL4009076 | 0.84 | MAP2K4 (0.48) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL4010483 | 0.83 | CHEK2 (0.52) | MAP2K4LNPEPMEN1KMT2ACYP1A2 | |
| SCHEMBL26715246 | 0.83 | ALDH1A1 (0.50) | MAP2K4MEN1KMT2AHTR6KIT | |
| SCHEMBL4013430 | 0.82 | MAP2K4 (0.53) | MAP2K4LNPEPMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4643910-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | claimed |
| JP-2005533004-A | — | — | 2005-11-04 | — | — | JP | claimed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | claimed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | claimed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MAP2K4 340/4885LNPEP 4312/4885MEN1 2247/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MAP2K4 328/4885LNPEP 4451/4885MEN1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.